cinacalcet (sensipar) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

  • Now
Cinacalcet is a positive allosteric modulator of calcium sensing receptor. The drug is approved by FDA (Sensipar trade name) and used for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis; hypercalcemia in adult patients with parathyroid carcinoma; hypercalcemia in adult patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.   NCATS

  • SMILES: C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c2cccc3ccccc23
  • Mol. Mass: 357.42
  • ALogP: 6.14
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)


$1.2828 - $3.8488

United States

$3.6673 - $52.6990
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

amg 073 | amg-073 | amg-073 hcl | cinacalcet | cinacalcet hcl | cinacalcet hydrochloride | cnc | krn1493 | mimpara | n-((1r)-1-(naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine | (r)-alpha-methyl-n-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine | regpara | sensipar


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue